Andrew Kuykendall, MD
Assistant Member, Malignant Hematology Department
Moffitt Cancer Center and Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida
Tracy I. George, MD
Professor of Pathology
University of Utah School of Medicine
President and Chief Scientific Officer
ARUP Laboratories
Salt Lake City, Utah

Program Description

Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; however, the heterogeneous clinical presentation and complex nature of SM-AHN can delay diagnosis and, therefore, treatment. This engaging educational activity provides concise and practical information about SM-AHN in a coffee-talk style format, examining the pathogenesis and challenges in diagnosis, as well as the factors that influence prognosis and therapeutic decision-making in patients with SM-AHN. 

Target Audience

The educational design of this activity addresses the needs of hematopathologists, hematologists, oncologists, and other specialist clinicians, including oncology nurses and pharmacists, in a position to identify, manage, and treat patients with advanced SM. 

Educational Objectives 

After completing this activity, the participant should be better able to:

  1. Describe the pathogenesis and relevant driver mutations in SM and their integral role in diagnosis, prognosis, and treatment
  2. Assess strategies to improve diagnosis of SM-AHN in patients with incidentally found KIT mutations
  3. Examine the heterogeneous clinical, molecular, and cytogenetic presentations of SM-AHN and how they influence prognosis and management
  4. Discuss clinical profiles and trial evidence for current and emerging targeted treatment options in advanced SM
  5. Evaluate strategies to overcome treatment challenges specific to SM-AHN and develop individualized treatment regimens that improve median overall survival

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

This educational activity for 0.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education (Universal Activity Number - 0530-9999-23-059-H01-P). This is a knowledge-based activity.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC and ACPE credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.
  5. Pharmacists must check the CPE Monitor for credits within 60 days of the activity. Credit for pharmacists cannot be issued after 60 days.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Integritas and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas and Global Education Group. All financial relationships reported are identified as relevant and mitigated by Integritas and Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas and Global Education Group to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Andrew Kuykendall, MD: Consulting Fees: Blueprint Medicines Corporation, Cogent Biosciences, Inc., Novartis; Contracted Research: Blueprint Medicines Corporation, Novartis

Tracy I. George, MD: Consulting fees: Allakos Inc, Blueprint Medicines Corporation, BluPrint Oncology Concepts, Celgene Corporation, CM Group Inc., E Squared Communications, Incyte Corporation, UBC (United BioSource LLC); Contracted Research: Blueprint Medicines Corporation, Celgene Corporation, Cogent Biosciences, Inc., Deciphera Pharmaceuticals, Inc., Incyte Corporation; all received by ARUP Laboratories

The planners and managers at Integritas and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas and Global Education Group do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Begin Activity
available resources
linked resources
Suggested Reading
Monday Morning Joe

LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management

A Monday Morning Joe Online Educational Activity